drug · antibody drug conjugate
patritumab deruxtecan
Phase 3updated 5mo agoby Daiichi Sankyo Co Ltd🔗 ChEMBL
Phase 3community read0 votes
Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and 6 investigational indications.
indications
indications
NSCLC
targets
Receptor tyrosine-protein kinase erbB-3DNA topoisomerase 1
all catalysts(0)
nothing on the calendar yet
Trials studying patritumab deruxtecan
- phase2A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- phase3HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
- phase3A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- phase2A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
- phase2Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
- phase2Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- phase2A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- phase2HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
News(3)
- Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B dealDaiichi Sankyo and Merck & Co. have withdrawn an antibody-drug conjugate (ADC) filing after the FDA said they lacked the data for accelerated approval in a lung cancer population.fiercebiotech · 6d ago
- Daiichi’s pipeline falls behind rivals as cash flow nears peak: analystsWith Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.biospace · 2mo ago
- Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer CongressExperts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.onclive · 5mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that